World Journal of Urology

, Volume 3, Issue 4, pp 215–217 | Cite as

Immunotheapy and immunodiagnostic studies in carcinoma of the bladder

  • Michael F. Sarosdy
  • Steven H. Pickett
  • Brian J. Stogdill
  • Marianne G. Rochester
  • Rex H. Reynolds
  • Howard M. Radwin
  • Donald L. Lamm
Article
  • 24 Downloads

Summary

Non-specific immunotherapy of superficial bladder cancer using Bacillus Calmette-Guérin (BCG) represents a successful application of immunotherapy against a human cancer. Clinical studies in the late 1970's first demonstrated the efficacy of this form of therapy against papillary forms of transitional cell carcinoma. Subsequent studies confirmed the value of BCG in extending the time to recurrence and decreasing both the rate of recurrence and the rate of progression of recurrent tumor to higher stages. These studies also showed BCG to be effective against carcinoma in situ. However, the mechanism of action of BCG has not yet been defined, nor has the optimal dosage schedule and route of administration been determined. Preliminary laboratory studies of tumor-specific therapy with tumor-derived protein extracts are encouraging, and suggest that this form of immunotherapy may be almost as efficacious as BCG therapy. Clinical trials of intravesical alpha-2 interferon for carcinoma in-situ are also in progress.

Keywords

Carcinoma Interferon Bladder Cancer Human Cancer Recurrent Tumor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brosman SA (1985) The use of Bacillus Calmette-Guérin in the therapy of bladder carcinoma in situ. J Urol 134:36–39Google Scholar
  2. 2.
    Brown KG, Reichert DF, Pickett SH, Lucio RM, Lamm DL (1985) Antibody targeted liposome chemotherapy of murine transitional cell carcinoma. 80th Annual Meeting of the American Urological Association, Atlanta, Georgia 269AGoogle Scholar
  3. 3.
    Coon JS, Weinstein RS (1981) Detection of ABH tissue isoantigens by immunoperoxidase methods in normal and neoplastic urothelium. Comparison with the erythrocyte adherence method. Am J Clin Pathol 76:163Google Scholar
  4. 4.
    Coon JS, Weinstein RS (1981) Variability in the expression of the 0(H) antigen in human transitional epithelium. J Urol 125:301Google Scholar
  5. 5.
    DeCenzo JM, Howard P, Irish CE (1975) Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma. J Urol 114:874Google Scholar
  6. 6.
    Droller MJ (1985) Immunotherapy in genitourinary neoplasia. J Urol 133:1–5Google Scholar
  7. 7.
    Hsu SM, Cossman J, Jaffe ES (1983) A comparison of ABC, unlabeled antibody and conjugated immunohistochemical methods with monoclonal and polyclonal antibodies-an examination of germinal center of tonsils. Am J Clin Pathol 80:429Google Scholar
  8. 8.
    Johnson JD, Lamm DL (1980) Prediction of bladder tumor invasion with the mixed cell agglutination test. J Urol 123:25–28Google Scholar
  9. 9.
    Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM (1985) Intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer: effect of Bacillus Calmette-Guérin viability on treatment results. J Urol 134:48–53Google Scholar
  10. 10.
    King CT, Clark, TD, Lovett J, Cash JB, Primus FJ, McRoberts JW, Flanigan RC (1983) A comparison of clinical course with blood group antigen testing by specific red cell adherence and immunoperoxidase in ureteral and renal pelvic tumors. J Urol 130:871Google Scholar
  11. 11.
    Lamm DL (1985) Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol 134:40–47Google Scholar
  12. 12.
    Lamm DL, Thor DE, Harris, SC, Reyna JA, Stogdill VD, Radwin HM (1980) Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 124:38–42Google Scholar
  13. 13.
    Lamm DL, Lucio RM, Reichert DF, Pickett SH (1984) Oral versus intralesional BCG immunotherapy of murine transitional cell carcinoma. 79th Annual Meeting of the American Urological Association, New Orleans, Louisiana 113AGoogle Scholar
  14. 14.
    Lamm DL, Crawford ED, Montie JE, Scardino PT, Stanisic TH, Grossman HB, Sullivan JW (1985) BCG vs Adriamycin in the treatment of transitional cell carcinoma in situ: A Southwest Oncology Group Study. 80th Annual Meeting of the American Urological Association, Atlanta, Georgia 184AGoogle Scholar
  15. 15.
    Lange PH, Limas C, Fraley EE (1978) Tissue blood group antigens and prognosis in low stage transitional cell carcinoma of the bladder. J Urol 119:52Google Scholar
  16. 16.
    Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116:180Google Scholar
  17. 17.
    Netto NR Jr, Lemos GC (1983) A comparison of treatment methods for the prophylaxis of recurrent superficial bladder tumors. J Urol 129:33–38Google Scholar
  18. 18.
    Reynolds RH, Stogdill VD, Lamm DL (1985) Disease progression in BCG treated patients with transitional cell carcinoma of the bladder. 80th Annual Meeting of the American Urological Association, Atlanta, Georgia 211AGoogle Scholar
  19. 19.
    Richie JP, Blute RD Jr, Waisman J (1980) Immunologic indicators of prognosis in bladder cancer: the importance of the cell surface antigens. J Urol 123:22Google Scholar
  20. 20.
    Rochester MG, Reichert DF, Fowlkes JL, Pickett SH, Lucio RM, Lamm DL (1985) Immunotherapy of murine transitional cell carcinoma with butanol-extracted antigens. 80th Annual Meeting of the American Urological Association, Atlanta, Georgia 268AGoogle Scholar
  21. 21.
    Seal GM, Rowland RG, Thomalla JV, Rudolph RA, Pfaff DS, Kamer M, Eble JN (1985) A, B and H antigens in normal urothelium: An immunohistochemical study using monoclonal antibodies with the avidin-biotin complex technique. J Urol 133:513–516Google Scholar
  22. 22.
    Simmons WB, Reichert DF, Lucio RM, Lamm DL (1983) Pyrimidinone interferon inducers in the treatment of murine transitional cell carcinoma. 78th Annual Meeting of the American Urological Association, Las Vegas, Nevada 169AGoogle Scholar
  23. 23.
    Stogdill BJ, Reichert DF, Lucio RM, Pickett SH, Lamm DL (1985) Ethylchlorformate polymerized tumor proteins and BCG in the immunotherapy of murine bladder cancer. 80th Annual Meeting of the American Urological Association, Atlanta, Georgia 267AGoogle Scholar
  24. 24.
    Torti F, Shortliffe L, Williams R, Spaulding I, Hannigan J, Palmer J, Meyers F, Higgins M, Freiha F (1984) Superficial bladder cancers are responsive to alpha-2 interferon administered intravesically. ASCO, Toronto 3:160Google Scholar
  25. 25.
    Winters WD, Lamm DL (in press) BCG induced circulating interferon antibody and immune complexes in bladder cancer patients during immunotherapy. International Cong ProcGoogle Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • Michael F. Sarosdy
    • 1
    • 2
  • Steven H. Pickett
    • 1
    • 2
  • Brian J. Stogdill
    • 1
    • 2
  • Marianne G. Rochester
    • 1
    • 2
  • Rex H. Reynolds
    • 1
    • 2
  • Howard M. Radwin
    • 1
    • 2
  • Donald L. Lamm
    • 1
    • 2
  1. 1.Division of Urology, Department of SurgeryThe University of Texas Health Science Center at San AntonioSan AntonioUSA
  2. 2.Department of UrologyWest Virginia UniversityMorgantownUSA

Personalised recommendations